Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prevalence rate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    217 result(s) found for: Prevalence rate. Displaying page 3 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-005586-40 Sponsor Protocol Number: NL79407.091.21 Start Date*: 2022-05-30
    Sponsor Name:Radboudumc
    Full Title: Colchicine and Inflammation in Aortic Stenosis
    Medical condition: Aortic stenosis (AS) is the most common valvular heart disease in the developed world. The prevalence of aortic sclerosis in the general population is estimated to be 25% at the age of 65 years and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001420-19 Sponsor Protocol Number: CINC280D2201 Start Date*: 2019-01-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adul...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) FR (Completed) GR (Completed) BG (Completed) NL (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002475-35 Sponsor Protocol Number: BO42353 Start Date*: 2021-06-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYND...
    Medical condition: Atypical Hemolytic Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10079841 Atypical hemolytic uremic syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000900-38 Sponsor Protocol Number: FT01CARCIK Start Date*: 2017-08-16
    Sponsor Name:FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS
    Full Title: Open label, single arm, multicenter, dose escalation Phase I-IIa, trial to determine the safety of Allogeneic (donor derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 C...
    Medical condition: Relapsed or Refractory B cell Acute Lymphoblastic Leukemia after Haematopoietic Stem Cell Transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006741-40 Sponsor Protocol Number: CNIC002A2201 Start Date*: 2008-07-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers...
    Medical condition: Smokers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003727-10 Sponsor Protocol Number: MO40598 Start Date*: 2019-12-16
    Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002829-29 Sponsor Protocol Number: ANRS174 Start Date*: 2019-12-12
    Sponsor Name:INSERM ANRS
    Full Title: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP)
    Medical condition: MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002114-40 Sponsor Protocol Number: APHP200527 Start Date*: 2020-07-30
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: Nintedanib for the treatment of SARS-Cov-2 induced pulmonary fibrosis
    Medical condition: Patients 2 to 6 months after Covid-19 acute pneumonia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005702-22 Sponsor Protocol Number: IELSG39 Start Date*: 2013-03-17
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
    Full Title: International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication moni...
    Medical condition: Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004895-21 Sponsor Protocol Number: WO42017 Start Date*: 2020-06-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER.
    Medical condition: Cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001429-30 Sponsor Protocol Number: WA42294 Start Date*: 2021-03-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) DE (Prematurely Ended) SE (Prematurely Ended) GR (Prematurely Ended) HU (Completed) PT (Prematurely Ended) AT (Prematurely Ended) FI (Completed) NO (Completed) DK (Prematurely Ended) PL (Completed) NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006430-39 Sponsor Protocol Number: BO43936 Start Date*: 2023-03-07
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED OPEN LABEL PHASE II STUDY OF IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    25.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086821 Advanced renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001028-32 Sponsor Protocol Number: CIVI/2018/NH-01 Start Date*: 2020-09-09
    Sponsor Name:CHU DE NIMES
    Full Title: Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable,...
    Medical condition: The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004845-25 Sponsor Protocol Number: BO29561 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and ritu...
    Medical condition: Follicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016737-95 Sponsor Protocol Number: ROSPREC Start Date*: 2011-07-13
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: ROSuvastatin Pretreatment to Reduce Embolization during Carotid Artery Stenting
    Medical condition: Asymptomatic carotid stenosis >80% in patients with baseline LDL cholesterol >120 mg/dL.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001364-19 Sponsor Protocol Number: BO29563 Start Date*: 2015-12-15
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffu...
    Medical condition: Follicular lymphoma or diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 100000004864 10016904 Follicle centre lymphoma, follicular grade I, II, III NOS LLT
    20.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000207-90 Sponsor Protocol Number: P15-14/BF2.649 Start Date*: 2016-11-24
    Sponsor Name:BIPROJET PHARMA
    Full Title: A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment.
    Medical condition: Patients with moderate to severe alcohol use disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10001584 Alcohol abuse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002334-23 Sponsor Protocol Number: 2017-03 Start Date*: 2017-09-29
    Sponsor Name:Dutch Breast Cancer Research Group (BOOG)
    Full Title: Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial
    Medical condition: hormone receptor positive advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003434-36 Sponsor Protocol Number: GS-US-590-6154 Start Date*: 2022-03-23
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Prev...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) HU (Prematurely Ended) BE (Completed) FR (Completed) AT (Prematurely Ended) PL (Prematurely Ended) NL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2021-003380-95 Sponsor Protocol Number: CDYP688A12101 Start Date*: 2022-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
    Medical condition: MUM and other non-uveal, GNAQ/11 mutant melanomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) NO (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 10:44:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA